Tirzepatide’s Prediabetes and Hypertension Impact
CardiacWire
AUGUST 23, 2024
It looks like we might be able to add prediabetes and hypertension to the growing list of conditions that Eli Lilly’s “weight loss drug” tirzepatide is able to treat, after new analysis of the SURMOUNT-1 trial showed significant reductions in blood pressure and diabetes progression. mm Hg systolic and 4.2
Let's personalize your content